Thursday, July 10, 2025 1:17:24 PM
There are many here who'd cast doubts on all that's happened over more than a decade, some who'd remind us of LP's association with Enron, and make it sound like she was involved in their fraud. The point is, it doesn't matter what you think or say, you can bring up the flaws in the trial, the revisions, say all you wish.
There is only one thing that matters, it's the decision of the regulators.
I can't say how much longer they'll take; our ultimate success doesn't occur until the last of them has said yes and DCVax-L has become a part of the SOC around the world and in every form of cancer it's determined to be effective in. That ultimate success may take decades to occur, and all that means is that the revenue next year will be greater than the revenue this year.
Once this becomes recognized, I believe that NWBO will warrant a P/E of 30 or more. With revenue growing year after year the stock price will certainly follow. This should prove to be one of the greatest investments in a lifetime, if it isn't bought out, but if it is, it still will have been a great ride for those involved now, and a good one for those who get involved at say under $10.
By the time NWBO exceeds $10 it's likely that over half of it will be Institutionally owned, at some point it may go to over 90%, so most of us will have sold out. We'll have made the greatest percentage growth, but Institutions will make the greatest dollar growth, and that's the way of the world. All you have to do is look at the Institutional ownership of the greatest companies and you'll see it everywhere, individual investors are just along for the ride.
Right now, almost no Institutional investors are in, but look at it when we're $2, $5 and up and watch it grow. When the Institutions start coming in the upward move could be massive.
Gary
There is only one thing that matters, it's the decision of the regulators.
I can't say how much longer they'll take; our ultimate success doesn't occur until the last of them has said yes and DCVax-L has become a part of the SOC around the world and in every form of cancer it's determined to be effective in. That ultimate success may take decades to occur, and all that means is that the revenue next year will be greater than the revenue this year.
Once this becomes recognized, I believe that NWBO will warrant a P/E of 30 or more. With revenue growing year after year the stock price will certainly follow. This should prove to be one of the greatest investments in a lifetime, if it isn't bought out, but if it is, it still will have been a great ride for those involved now, and a good one for those who get involved at say under $10.
By the time NWBO exceeds $10 it's likely that over half of it will be Institutionally owned, at some point it may go to over 90%, so most of us will have sold out. We'll have made the greatest percentage growth, but Institutions will make the greatest dollar growth, and that's the way of the world. All you have to do is look at the Institutional ownership of the greatest companies and you'll see it everywhere, individual investors are just along for the ride.
Right now, almost no Institutional investors are in, but look at it when we're $2, $5 and up and watch it grow. When the Institutions start coming in the upward move could be massive.
Gary
Bullish
Recent NWBO News
- How Advanced Drug Delivery Could Improve Existing Cancer Treatments • GlobeNewswire Inc. • 06/01/2026 12:30:00 PM
- CNS Drug Delivery Breakthroughs Unlock Significant Biotech Market Opportunities • InvestorsHub NewsWire • 05/11/2026 01:00:00 PM
- CNS Drug Delivery Breakthroughs Unlock Significant Biotech Market Opportunities • GlobeNewswire Inc. • 05/11/2026 12:30:00 PM
- Northwest Biotherapeutics Appoints Dr. Annalisa Jenkins As Strategic Adviser To Advance Dendritic Cell Cancer Vaccine Platform • PR Newswire (US) • 04/30/2026 04:38:00 PM
- Northwest Biotherapeutics Appoints Dr. Annalisa Jenkins As Strategic Adviser To Advance Dendritic Cell Cancer Vaccine Platform • PR Newswire (US) • 04/30/2026 04:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 04/21/2026 04:15:08 AM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 04/16/2026 09:25:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
